Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Company Overview
Harrow Health Inc (HROW) is an innovative eyecare pharmaceutical company focused on addressing unmet medical needs through the discovery, development, production, and commercialization of specialized ophthalmic formulations and therapeutic products across the United States. Operating at the intersection of advanced research and clinical application, the company brings together deep industry expertise, rigorous R&D, and a commitment to improving patient care.
Business Model and Operations
At its core, Harrow Health provides a comprehensive portfolio that blends ophthalmology-based drug development with non-intravenous sedation and anesthesia therapeutics for a variety of medical procedures. Its operations are structured around:
- Ophthalmic Therapeutics: Focusing on the management of ocular surface diseases, the company develops topical eye drop formulations that serve both preventative and therapeutic roles.
- Compounded Medications: Offering both sterile and non-sterile formulations, it meets the needs of physicians seeking tailored solutions for diverse clinical scenarios.
- Non-Intravenous Sedation: Developing products designed to facilitate conscious sedation during procedures such as cataract surgery, thereby enhancing patient comfort and procedural efficiency.
This multi-pronged approach not only diversifies its product portfolio but also creates a resilient business model that appeals to healthcare professionals and institutions across outpatient, in-office, and hospital settings.
Market Position and Competitive Landscape
Harrow Health Inc has carved a niche within the highly regulated US pharmaceutical market. Its strategic focus on ocular and sedation therapeutics differentiates it from broader scale pharmaceutical companies, while its commitment to advanced research and quality production standards reinforces its reputation among eyecare professionals. In a competitive landscape where precision and safety are paramount, Harrow Health’s integration of clinical insights with innovative drug formulations positions it as a noteworthy player devoted to addressing specific medical challenges effectively.
Product Portfolio and Therapeutic Solutions
The company has developed an extensive range of products that address conditions related to the ocular surface and procedural sedation. Its portfolio includes:
- Topical Ophthalmic Formulations: Designed to manage diseases affecting the ocular surface and support rehabilitation of vision-related functions.
- Compounded Medications: Both sterile and non-sterile, these are tailored to meet precise medical requirements across various treatment settings.
- Sedation Therapeutics: Products intended for sublingual administration provide non-intravenous sedation, enabling safe and effective patient management during surgical procedures.
Research, Development, and Quality Assurance
The foundation of Harrow Health Inc’s operations lies in robust research and development. The company continually refines its product offerings through comprehensive clinical research and adherence to stringent quality assurance protocols. Its approach underscores a commitment to safety and efficacy while addressing the evolving needs of healthcare providers and patients. This rigorous scientific methodology exemplifies the company’s dedication to maintaining high standards of regulatory compliance and industry best practices.
Commitment to Scientific Integrity and Patient Care
Across its diverse operations, Harrow Health demonstrates a sustained commitment to improving patient outcomes. The company’s emphasis on continuous innovation, strategic R&D, and quality-focused manufacturing processes helps ensure that its pharmaceutical solutions not only meet but often exceed industry benchmarks. This dedication to scientific integrity and patient well-being has established Harrow Health as a trusted entity within the field of eyecare therapeutics.
Strategic Value Proposition
Harrow Health Inc’s value proposition is rooted in its specialized expertise in ophthalmic formulations and sedation therapies. By addressing critical gaps in current medical treatments, the company supports healthcare providers in delivering effective and accessible care. Its balanced focus on innovation, quality, and clinical relevance positions it as a vital contributor to the pharmaceutical landscape, particularly within the realms of eye care and procedural sedation.
Overall, Harrow Health Inc exemplifies a dedicated, research-driven approach to pharmaceutical development that leverages deep industry expertise to meet unmet medical needs. Through its integrated operations and commitment to quality, it remains a significant, unbiased source of therapeutic solutions for healthcare professionals nationwide.
Harrow Health, Inc. (NASDAQ: HROW) announced participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Mark Baum and CFO Andrew Boll will engage in a virtual presentation available on the company's investor relations site starting March 9, 2021, at 7:00 a.m. ET, archived for 90 days. The management team will also hold one-on-one meetings via H.C. Wainwright. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leader in ophthalmology outsourcing and pharmaceutical compounding.
Harrow Health, Inc. (NASDAQ: HROW) announced it will release its fourth quarter and annual financial results for the year ending December 31, 2020, on March 8, 2021, after the market close. The financial results will be available on their website, and a conference call will occur at 4:45 p.m. ET to discuss the outcomes and present a business update. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leading ophthalmology outsourcing business.
Melt Pharmaceuticals announced positive results from its Phase 1 MELT study, which evaluated the pharmacokinetic parameters of its novel midazolam and ketamine formulation. The study met its objectives, demonstrating good tolerance and relative bioavailability. The company plans to meet with the FDA to finalize its clinical protocol and commence a Phase 2 study in the third quarter of 2021, targeting cataract surgery patients. If approved, this non-opioid and IV-free option could significantly change pain management during surgeries.
Harrow Health (NASDAQ: HROW) announced a study published in the AANA Journal demonstrating the effectiveness of its MKO Melt® troche as a non-opioid alternative for IV sedation in cataract surgeries. The study involved 107 patients, comparing MKO Melt to traditional sedation methods. Findings indicated comparable comfort levels between both sedation methods, promoting MKO Melt for patients, especially those with needle-phobia. The MKO Melt has been used in over 250,000 cataract surgeries and is available for purchase through ImprimisRx.
Harrow Health (NASDAQ: HROW) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. CEO Mark Baum and CFO Andrew Boll will present a corporate overview, with the management team available for one-on-one meetings. The pre-recorded presentation will be accessible to registered attendees from November 23 until December 3. Additionally, a replay of the conference presentation will be available for approximately 90 days on Harrow’s website.
Harrow Health (NASDAQ: HROW) reported exceptional financial results for Q3 2020, marking the best quarter in its history. Revenues increased month-over-month, achieving record gross margins and adjusted EBITDA. CEO Mark L. Baum expressed optimism about a continuous upward revenue trend heading into 2021, anticipating potential value inflection events. The company primarily focuses on ophthalmology through ImprimisRx and owns significant stakes in several pharmaceutical entities. A conference call discussing these results will be held on Nov. 9, 2020.
Harrow Health (NASDAQ: HROW) will announce its third quarter 2020 financial results after the market closes on November 9, 2020. A conference call will follow at 4:45 p.m. EST, providing an overview of the quarter and future outlook. Investors can access a press release and the company's Letter to Stockholders on its Investor Relations website. The call is intended for analysts to engage with the management team. Replay options for the call will be available until December 9, 2020, for dial-in listeners and until February 9, 2021, for webcast listeners.
Harrow Health (NASDAQ: HROW) will attend Lake Street’s 4th Annual Best Ideas Growth Conference on September 17, 2020, via a virtual platform. CEO Mark L. Baum and CFO Andrew Boll will be available for one-on-one meetings with investors throughout the day to discuss business updates. Interested parties should contact their Lake Street representative to arrange meetings or email conference@lakestreetcm.com for more information. Harrow Health owns a portfolio of healthcare businesses focused on patient-first solutions.
Harrow Health, Inc. (NASDAQ: HROW) announced its second quarter 2020 results, reporting a swift recovery post-COVID-19 impact. CEO Mark L. Baum highlighted record-high revenue days in Q3, attributed to effective product formulations and a new partnership with EyePoint Pharmaceuticals to market DEXYCU®. The company anticipates significant catalysts from Eton, Surface, and Melt in the coming months, bolstering optimism for shareholders.
Harrow Health (NASDAQ: HROW) will release its second quarter 2020 financial results on August 10, 2020, following the market close. A conference call is scheduled for 5:00 PM EDT to discuss these results and recent business developments. The press release will also include a link to the second quarter Letter to Stockholders, available on the Investor Relations website. A replay of the conference call will be accessible until September 10, 2020, with a webcast replay available until November 10, 2020.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
What is Harrow Health Inc's primary focus?
What types of products does the company offer?
How does Harrow Health Inc generate revenue?
What differentiates Harrow Health from its competitors?
In which market does Harrow Health primarily operate?
What role does research and development play in the company?
How does the company support clinical practices?
Can you explain the company’s approach to quality assurance?
